Pulmonary Embolism

Clinical Trial Finder

Many patients with pulmonary embolism are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)

Conditions:   Deep Vein Thrombosis;   Pulmonary Embolism
Interventions:   Drug: Dabigatran Etexilate Oral Capsule;   Drug: Rivaroxaban Oral Tablet;   Drug: Edoxaban Oral Tablet;   Drug: Apixaban Oral Tablet
Sponsors:   Danish Heart Foundation;   Danish Society of Cardiology
Not yet recruiting - verified April 2017

Development of a Questionnaire to Assess Patient Knowledge About Non-vitamin K Anticoagulants (NOAC)

Conditions:   Atrial Fibrillation;   Pulmonary Embolism;   Deep Vein Thrombosis
Intervention:   Behavioral: Education
Sponsors:   University Hospital, Basel, Switzerland;   University of Basel
Recruiting - verified April 2017

Apixaban in Preventing Secondary Cancer Related Blood Clots in Cancer Patients Who Have Completed Anticoagulation Therapy

Conditions:   Deep Vein Thrombosis;   Malignant Neoplasm;   Metastatic Malignant Neoplasm;   Pulmonary Embolism
Intervention:   Drug: Apixaban
Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
Not yet recruiting - verified April 2017

Microsurgical Breast Reconstruction & VTE

Conditions:   Breast Reconstruction;   Venous Thromboembolism
Intervention:   Diagnostic Test: Duplex ultrasound
Sponsors:   Stanford University;   University of Utah
Recruiting - verified April 2017

Investigating Trends in Compliance With Quality Assurance Metrics

Condition:   Postoperative Morbidity
Intervention:   Other: Receive metric feedback email
Sponsor:   University of Michigan
Completed - verified April 2017

Pulmonary Embolism Short-term Clinical Outcomes Registry

Condition:   Pulmonary Embolism
Intervention:  
Sponsor:   Carolinas Healthcare System
Recruiting - verified April 2017

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

Condition:   Anaemia
Interventions:   Drug: Daprodustat;   Drug: rhEPO;   Drug: Placebo;   Drug: Iron therapy
Sponsor:   GlaxoSmithKline
Recruiting - verified April 2017

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Condition:   Anaemia
Interventions:   Drug: Daprodustat;   Drug: Darbepoetin alfa;   Drug: Placebo;   Drug: Iron Therapy
Sponsor:   GlaxoSmithKline
Recruiting - verified April 2017

A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer

Condition:   Venous Thrombosis and Pulmonary Embolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY 59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified April 2017

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

Condition:   Venous Thromboembolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified April 2017

Evaluation of Soluble Fibrin in Thrombosis Exclusion

Conditions:   Pulmonary Embolism (PE);   Deep Vein Thrombosis (DVT)
Intervention:   Other: Soluble Fibrin
Sponsors:   Diagnostica Stago R&D;   Hôpital Louis Mourier;   Hopital Lariboisière
Recruiting - verified April 2017

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsors:   Bayer;   Janssen Scientific Affairs, LLC
Recruiting - verified April 2017

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Pegylated (PEG) L-Asparaginase

Conditions:   Lymphoma;   Acute Lymphoblastic Leukemia
Interventions:   Drug: Apixaban;   Other: No systemic anticoagulant prophylaxis
Sponsor:   Bristol-Myers Squibb
Recruiting - verified March 2017

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Placebo
Sponsors:   AstraZeneca;   FibroGen
Active, not recruiting - verified April 2017

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Epoetin alfa
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified April 2017

Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery

Condition:   Anticoagulation
Intervention:   Drug: Apixaban
Sponsors:   Bristol-Myers Squibb;   Pfizer
Recruiting - verified August 2016

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2017

Blood Markers of Inflammation, Blood Clotting and Blood Vessel Function in HIV-infected Adults

Condition:   HIV
Intervention:  
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 19, 2017

Development of Computer-aided Detection and Diagnosis From Imaging Techniques

Condition:   Cancer
Intervention:  
Sponsor:   National Institutes of Health Clinical Center (CC)
Completed - verified March 8, 2017

Hip Fracture Study of GSK576428 (Fondaparinux Sodium)

Condition:   Thromboembolism
Intervention:   Drug: Fondaparinux
Sponsor:   GlaxoSmithKline
Completed - verified April 2017

Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)

Condition:   Thrombosis, Venous
Intervention:   Drug: Fondaparinux
Sponsor:   GlaxoSmithKline
Completed - verified April 2017